11 |
Estudo do efeito da atorvastatina na mucosites oral induzida por 5-fluorouracil em hamsters. / Study of the effect of atorvastatin on 5-fluorouracil-induced oral mucositis in hamsters.Caroline Addison Carvalho Xavier 05 November 2010 (has links)
nÃo hà / A mucosite oral (MO) à um efeito colateral freqÃente e dose limitante da terapia do cÃncer, caracterizada por intensa reaÃÃo inflamatÃria na mucosa e formaÃÃo de Ãlceras na cavidade orofarÃngea. O objetivo deste trabalho foi avaliar o efeito da atorvastatina (ATV), droga utilizada para reduzir os nÃveis sÃricos de colesterol e que tem atividade antiinflamatÃria, na mucosite oral induzida por 5-fluorouracil (5-FU) em hamsters Golden Sirian. A mucosite oral foi induzida pela administraÃÃo intraperitoneal (i.p.) de 5-FU no 1 e 2 dias do experimento (60 e 40 mg/kg, respectivamente), com subseqÃentes escoriaÃÃes na mucosa jugal, no quarto dia. Os animais foram tratados intraperitonealmente (i.p.) com ATV 1, 5 ou 10 mg/kg ou salina ou salina/etanol 5% vol/vol 30 minutos antes de cada injeÃÃo do 5-FU e diariamente por 5 ou 10 dias. Os animais foram sacrificados no 5 ou 10 dia e amostras de mucosa jugal e dos principais ÃrgÃos vitais foram coletados para anÃlise histopatolÃgica. A determinaÃÃo dos nÃveis de TNF-α, IL-1β, nitrito, grupos sulfidrilas nÃo proteicos (NP-SH), ensaio da mieloperoxidase (MPO), imunohistoquÃmica para TNF-α, Ãxido nÃtrico sintase induzida (iNOS), NF-KB-p50, NF-kB-p50 NLS (sequÃncia de localizaÃÃo nuclear) e a expressÃo do NF-kB-p50 por Western Blot foram outros parÃmetros avaliados em amostras coletadas da mucosa jugal dos animais. O sangue foi coletado para leucograma, anÃlise dos parÃmetros bioquÃmicos e anÃlise da bacteremia. Atorvastatina nas doses de 1 e 5 mg/kg reduziu o dano na mucosa e a inflamaÃÃo, bem como os nÃveis de citocinas, nitrito e a atividade da MPO no 5 e 10 dia da MO. Ademais, atorvastatina 1 e 5 mg/Kg diminuiu a marcaÃÃo imunohistoquÃmica para TNF-α, NOSi, NF-kB-p50, NF-kB-p50 NLS, bem como a expressÃo do NF-kB-p50 na mucosa jugal dos hamsters submetidos a MO, no 5 dia. ATV 1 mg/Kg aumentou os nÃveis de NP-SH na mucosa jugal dos animais, quando comparado com os grupos 5-FU no 10 dia da MO. A associaÃÃo de ATV 5 mg/Kg e 5-FU diminuiu a taxa de sobrevida, amplificou a leucopenia dos animais, aumentou os nÃveis sÃricos de transaminases e causou lesÃo hepÃtica. NÃs tambÃm detectamos a presenÃa de bacilos Gram negativos no sangue de 100% dos animais tratados com ATV 5mg/Kg + 5-FU. Esses resultados sugerem que a atorvastatina previne o dano na mucosa oral e a inflamaÃÃo associada com MO induzida por 5-FU, entretanto a combinaÃÃo de altas doses de ATV com 5-FU induz hepatotoxicidade, amplificaÃÃo da leucopenia e bacteremia, que merecem atenÃÃo e futuros estudos em humanos. / Oral mucositis (OM) is a frequent side effect and dose-limiting of cancer therapy, characterized by intense inflammatory mucosal reaction and formation of ulcers in oropharyngeal cavity. The aim of this study was to evaluate the effect of atorvastatin (ATV) â cholesterol lowering drug with anti-inflammatory activity - in oral mucositis induced by 5-fluorouracil (5-FU) in Golden Sirian hamsters. Oral mucositis was induced by intraperitoneal (i.p.) administration of 5-FU in the first and second days of experiment (60 and 40 mg/kg i.p., respectively), with subsequent excoriations of the cheek pouch mucosa on the fourth day. The animals were treated by intraperitoneal route (i.p.) with ATV 1, 5 or 10 mg/kg or saline or saline and 5% vol/vol ethanol 30 min before 5-FU injection and daily for 5 or 10 days. The animals were sacrificed on the 5th or 10th day and samples of cheek pouches and major vital organs were removed for histopathological analysis. The determination of TNF-α, IL-1β, nitrite, non-protein sulfhydryl group (NP-SH) levels, myeloperoxidase (MPO) assay, immunohistochemistry for TNF-α, induced nitric oxide synthase (iNOS), NF-kB-p50, NF-kB-p50 NLS and the expression of NF-kB-p50 by Western Blot were other parameters evaluated in the samples collected from the oral mucosa of animals. Blood was collected for a leukogram, analysis of biochemical parameters and analysis of bacteremia. Atorvastatin at doses of 1 and 5 mg/kg reduced mucosal damage and inflammation, as well as the levels of cytokines, nitrite, and myeloperoxidase activity on the 5th and 10th day of OM. Moreover, ATV 1 and 5 mg/kg decreased the immunohistochemical staining for TNF-α, iNOS, NF-kB-p50, NF-kB-p50 NLS and expression of NF-kB-p50 of the cheek pouch mucosa on the 5th day of OM. ATV at 1 mg/kg increased cheek pouch NP-SH when compared to 5-FU groups on the 10th day of OM. The association of ATV 5 mg/kg and 5-FU decreased the survival rate, amplified the leukopenia of animals, increased transaminase serum levels and caused liver lesions. We also detected the presence of Gram negative bacillus in the blood of 100% of the animals treated with ATV 5 mg/kg + 5-FU. These results suggest that atorvastatin prevent mucosal damage and inflammation associated with 5-FU-induced OM, but the association of a higher dose of ATV with 5-FU induced hepatotoxicity, amplified leucopenia and bacteremia, which deserves attention and further research in humans.
|
12 |
Estudo dos efeitos da terapia combinada orlistat / cisplatina / 5-fluorouracil / paclitaxel em linhagem metastática de carcinoma espinocelular de língua / Effects of combined therapy Orlistat / Cisplatin/ 5-Fluorouracil / Paclitaxel in metastatic lineage of squamous cell carcinoma of the tongueMoreira, Fernanda dos Santos, 1986- 24 August 2018 (has links)
Orientador: Edgard Graner / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Odontologia de Piracicaba / Made available in DSpace on 2018-08-24T18:26:23Z (GMT). No. of bitstreams: 1
Moreira_FernandadosSantos_M.pdf: 1478167 bytes, checksum: 57f6f26580823a79292af5a274beaa2d (MD5)
Previous issue date: 2014 / Resumo: A ácido graxo sintase (FASN) é a principal enzima envolvida na lipogênese neoplásica e apontada como uma oncoproteína metabólica por favorecer o crescimento e sobrevivência das células tumorais, nas quais sua expressão é em geral elevada. Vários são os compostos capazes de inibir a atividade de FASN, dentre eles o orlistat (Xenical®), que possui efeitos antineoplásicos em cânceres de mama e próstata e nos melanomas. O carcinoma espinocelular (CEC) representa aproximadamente 90% de todas as neoplasias malignas que acometem a cavidade oral, sendo diagnosticado em estágios avançados em grande parte dos casos. Nestes pacientes, geralmente com metástases, é realizada uma abordagem sistêmica com agentes quimioterápicos como a cisplatina, o 5-fluorouracil (5-FU) e o paclitaxel, de maneira isolada ou combinada. Este trabalho tem como objetivo investigar in vitro se cisplatina, 5-FU ou paclitaxel potencializam o efeito antitumoral do orlistat no CEC oral. Para isto, células de CEC de língua altamente metastáticas (SCC-9 LN1) foram tratadas com estas drogas isoladamente ou combinadas com orlistat e avaliadas com relação às taxas de apoptose e necrose, progressão do ciclo celular e secreção de VEGFA e VEGFA165b. As maiores taxas de apoptose foram encontradas com o uso da combinação de orlistat com paclitaxel, após 48 horas de tratamento. Com relação ao ciclo celular, houve acúmulo de células na fase S com a combinação de orlistat com cisplatina e na fase G2 com a combinação de orlistat com paclitaxel. O tratamento das células SCC-9 LN1 com os agentes quimioterápicos reduziu a secreção dos fatores VEGFA e VEGFA165b, em comparação ao tratamento com orlistat isolado ou em combinação. Em conjunto, estes resultados mostram a existência de sinergismo na combinação de orlistat com paclitaxel com evidente potencialização do efeito pró-apoptótico nas células derivadas de CEC oral metastático / Abstract: Fatty acid synthase (FASN) is the main enzyme involved in the neoplastic lipogenesis. The expression of FASN is elevated in many tumor cells, suggesting a role as a metabolic oncoprotein, with the ability to promote growth and survival of tumor cells. There are several compounds that inhibit FASN activity, including orlistat. Orlistat has evident antineoplastic effects in breast and prostate cancers, as well as melanomas. Oral squamous cell carcinoma (OSCC), corresponds to approximately 90% of all cancers that affect the oral cavity, and is diagnosed in advanced stages in most cases. Distant metastases of OSCC are systemically treated with chemotherapeutic agents, such as cisplatin, 5-fluorouracil (5-FU) and paclitaxel. This study aims to investigate the in vitro antitumor effect of orlistat combined with cisplatin, 5-FU and/or paclitaxel in OSSC cells. Highly metastatic tongues squamous cell carcinoma cells (SCC-9-LN1) were treated with these drugs separately or combined with orlistat, in concentrations close to their respective IC50. Next, the cultures were evaluated regarding the rates of cell death (apoptosis and necrosis), cell cycle progression and the secretion VEGFA and VEGFA165b. The highest rate of apoptosis was observed with the combination of orlistat and paclitaxel, after 48 hours of treatment. Cell cycle analysis assay demonstrate as an accumulation of cells SCC-9 LN1 in the S phase, after incubation with the combination of orlistat with cisplatin, and in the G2 phase with orlistat plus paclitaxel. The 5-FU alone, promoted accumulation of cells in the G1/S. Additionally, secretion of VEGFA and was VEGFA165b was inhibited in SCC-9-LN1cells by the combined treatments. These results demonstrate the synergism existence of the mixture orlistat and paclitaxel with potentiation of their pro-apoptotic effects in SCC-9 LN1 cells / Mestrado / Estomatologia / Mestra em Estomatopatologia
|
13 |
Preparação e caracterização de nano-esferas de PLGA contendo 5-fluorouracil e estudo do acoplamento de quitosana e ácido fólico em sua superfície / Preparation and characterization of PLGA nanospheres containing 5-fluorouracil and study of chitosan and folic acid attachment on their surfaceCalderini, Adriana 19 August 2018 (has links)
Orientador: Francisco Benedito Teixeira Pessine / Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Química / Made available in DSpace on 2018-08-19T02:12:00Z (GMT). No. of bitstreams: 1
Calderini_Adriana_D.pdf: 8667238 bytes, checksum: 93c066670f54801635af79d770afae4c (MD5)
Previous issue date: 2011 / Resumo: 5-Fluorouracil (5-FU) e um dos fármacos mais úteis no tratamento de tumores sólidos em adultos, especificamente carcinomas do trato gastrointestinal (estômago, cólon e reto) e da mama. Em resumo, seu maior efeito bioquímico e a inibição da síntese do DNA, pois a concentração que inibe sua síntese pode ainda permitir a sintese do RNA. Causa severos efeitos adversos como mielo supressão, mucosite, dermatite, diarréia e toxicidade cardíaca. Em razão disto, têm sido realizadas várias tentativas para encapsular 5-FU a fim de reduzir os efeitos adversos que ele provoca. O objetivo deste projeto foi encapsular este anti-neoplásico utilizando nano-esferas de ácido poli(lático-co-glicólico), PLGA, como sistema carreador, acoplando à sua superfície quitosana e folato de quitosana para melhor endereçamento aos locais de ação, bioadesividade e menor toxicidade. A encapsulação de 5-FU em nano-esferas de PLGA foi aperfeiçoada através de planejamento experimental e por análise quimiométrica. Muitos fatores foram estudados: métodos de preparação, temperatura, quantidade inicial de 5-FU e pH. Na caracterização destes sistemas foram utilizadas diversas técnicas: espalhamento dinâmico de luz, determinação do potencial Zeta, calorimetria diferencial de varredura, análise termogravimétrica, difratometria de raios-X e microscopia eletrônica de varredura. Além disso, foram realizados ensaios de perfil de liberação, de estabilidade coloidal e estudo do comportamento desses sistemas em relação às células in vitro. O planejamento experimental permitiu obter nanoparticulas com capacidade de carregamento em torno de 11% e eficiência de encapsulação de 32%. O acoplamento de quitosana e folato de quitosana permitiu retardar a liberação do fármaco em solução. Para armazenagem destas partículas, observou-se que elas foram menos degradadas quando estão liofilizadas e mantidas a 4 °C. A melhor concentração de sacarose para liofilizá-las, sem que ocorra aumento de tamanho e polidispersão, foi 250 mmol/L. Os testes in vitro comprovaram a eficácia destas formulações / Abstract: 5-fluorouracil (5-fluoro-1H-pyrimidine-2,4-dione) is one of the most used drug to treat solid tumors in adults, specifically gastrointestinal (stomach and colorectal) and breast carcinomas. In summary, the major biochemical effect of 5-FU is inhibition of DNA synthesis, since concentrations which inhibit this synthesis may still permit RNA synthesis. It causes severe adverse effects as myelosuppression, mucositis, dermatitis, diarrhea and cardiac toxicity. Its encapsulation in nanoparticles can reduce these adverse effects, prolong its release and the drug can be placed directly on its site of action. The goal of this work was to encapsulate this anti-neoplasic drug using poly (lactic-co-glycolic acid) PLGA nanospheres as carrier system, attaching on their surface chitosan and folate-chitosan to attain an enhanced targeting, bioadesivity and less toxicity. The encapsulation of 5-FU in PLGA nanospheres was improved through an experimental design and chemometry. Many factors were studied: methods of preparation, temperature, initial amount of 5-FU and pH. In the characterization, many techniques were employed: dynamic light scattering, determination of Zeta potential, differential scanning calorimetry, thermo gravimetric analysis, X-ray difractometry and scanning electron microscopy. Besides, we also analyzed the release profile, colloidal stability and the behavior of these systems in relation to in vitro cancer cells. The experimental design allowed obtaining nanoparticles with drug loading around 11% and encapsulation efficiency of 32%. The attachment of chitosan and folate-chitosan also allowed prolonging the drug release in solution. To store these formulations, we observed that lyophilized particles kept at 4 °C were less degraded. The best sucrose concentration to freeze-drying these particles with no size and polidispersity change was 250 mmol/L. The in vitro tests proved the efficacy of these formulations / Doutorado / Físico-Química / Doutor em Ciências
|
14 |
Efeito da suplementação com l-arginina no peso corporal, hemograma e na produção das imunoglobulinas de ratos submetidos à quimioterapia / Effect of l-arginine supplementation on body weight, hemogram and production of immunoglobulins in rats subjected to chemotherapyBALMANT, Bianca Depieri 29 November 2016 (has links)
Submitted by Adriana Martinez (amartinez@unoeste.br) on 2017-08-15T19:12:52Z
No. of bitstreams: 2
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Bianca.pdf: 748434 bytes, checksum: 25858a86b136011052140d31f626de30 (MD5) / Made available in DSpace on 2017-08-15T19:12:52Z (GMT). No. of bitstreams: 2
license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Bianca.pdf: 748434 bytes, checksum: 25858a86b136011052140d31f626de30 (MD5)
Previous issue date: 2016-11-29 / The purpose of this study was to evaluate the effect of supplementation with L-arginine, in different doses, on body weight, hemogram, production of IgA, IgG and IgM immunoglobulins and in the small bowel inflammatory process of Wistar rats subjected to chemotherapy. A total of 32 Rattus novergicus Wistar rats were randomly distributed in 4 groups (8 rats / group) with similar body weight: control group (CG), the rats were given ration and water; G5-FU was given ration, water and a dose of 5-FU; Garg295 + 5-FU and Garg458 + 5-FU were given, respectively, 295 mg and 458 mg of L-arginine, which was added to the water and a dose of 5-FU. 5-FU was applied after the adaptation period (day 7) in a single dose of 200 mg of 5-FU / kg body weight, intraperitoneally. The rats were weighed individually, always in the morning and without previous fasting, to determine the weight gain before and after the application of 5-FU. Four days after application of 5-FU, the rats were anesthetized with thionembutal, blood and small intestine samples were collected. Supplementation with 295 mg of L-arginine was shown to be beneficial in reducing body weight loss during treatment with the 5-FU chemotherapeutic. The concentration of platelets was lower (P <0.05) in the G5-FU and GArg458 + 5-FU groups, but similar between the GC and GArg295 + 5-FU groups. The total leukocyte concentration showed a significant reduction in the G5-FU, GArg295 + 5-FU and GArg458 + 5-FU groups when compared to the GC group, however, there was a significant reduction of neutrophils only in the G5-FU group. There was an increase (P <0.05) in fibrinogen concentration in the groups treated with L-arginine (GArg295 + 5-FU and GArg458 + 5-FU). In the GArg295 + 5-FU and GArg458 + 5FU groups, the serum IgA concentration increased significantly in relation to the G5-FU group. Rats supplemented with L-arginine had a minor inflammatory process in the small intestine. It was concluded that supplementation with 295 mg of L-arginine / day attenuated the immediate body weight loss of Wistar rats subjected to 5-FU chemotherapy and that daily supplementation with both 295 mg and 458 mg of L-arginine may ease some side effects of 5-FU such as thrombocytopenia, neutropenia and immunomodular production of IgA, in addition to reducing intestinal inflammatory processes. / Este estudo teve o objetivo deste estudo foi avaliar o efeito da suplementação com L-arginina, em diferentes doses, no peso corporal, no hemograma, na produção das imunoglobulinas IgA, IgG e IgM e no processo inflamatório do intestino delgado de ratos Wistar submetidos à quimioterapia. Foram utilizados 32 Rattus novergicus da linhagem Wistar, distribuídos aleatoriamente em 4 grupos (8 ratos/grupo) com peso corporal semelhante: grupo controle (GC), os ratos receberam ração e água; G5-FU receberam ração, água e uma dose de 5-FU; Garg295+5-FU e Garg458+5-FU que receberam ração, 295 mg e 458 mg de L-arginina, respectivamente, adicionada na água e uma dose de 5-FU. A 5-FU foi aplicada após o período de adaptação (dia 7) na dose única de 200 mg de 5-FU/Kg de peso corporal, por via intraperitoneal. Os ratos foram pesados individualmente, sempre no período da manhã e sem jejum prévio, para determinação do ganho de peso antes e depois da aplicação da 5-FU. Quatro dias após da aplicação da 5-FU, os ratos foram anestesiados com tionembutal e colheu-se amostras de sangue e do intestino delgado. A suplementação com 295 mg de L-arginina mostrou-se benéfica na redução de perda de peso corporal durante o tratamento com o quimioterápico 5-FU. A concentração de plaquetas foi menor (P < 0,05) nos grupos G5-FU e GArg458+5-FU, porém, semelhantes entre os grupos GC e GArg295+5-FU. A concentração de leucócitos totais apresentou redução significativa nos grupos G5-FU, GArg295+5-FU e GArg458+5-FU quando comparados ao grupo GC, entretanto, houve redução significativa de neutrófilos somente no grupo G5-FU. Ocorreu um aumento (P < 0,05) na concentração de fibrinogênio nos grupos tratados com L-arginina (GArg295+5-FU e GArg458+5-FU). Nos grupos GArg295+5-FU e GArg458+5FU, a concentração sérica de IgA aumentou significativamente em relação ao grupo G5-FU. Os ratos suplementados com L-arginina apresentaram menor processo inflamatório no intestino delgado. Conclui-se que a suplementação com 295 mg de L-arginina/dia atenuou a perda de peso corporal imediata dos ratos Wistar submetidos à quimioterapia com 5-FU e que a suplementação diária tanto com 295 mg como 458 mg de L-arginina pode amenizar alguns efeitos colaterais da 5-FU como a plaquetopenia, a neutropenia e imunomodular a produção de IgA, além de reduzir processos inflamatórios intestinais.
|
15 |
Effect of Sodium Salicylate, Cisplatin and 5-Fluorouracil in LMP1-Overexpressed Nasopharyngeal Carcinomas Cell LinesTsai, Hsien-chu 21 June 2012 (has links)
Nasopharyngeal carcinomas (NPC) is highly induced by Epstein-Barr virus (EBV). EBV infection encoded latent membrane protein 1 (LMP1) is expressed in latent stage II and III of EBV infection nasopharyngeal cells. LMP1 was reported to be associated with increased tumorigenesis, through the activation of nuclear factor-£eB (NF-£eB). In this study, LMP1 overexpressing NPC cell line (TW04) was used for assays of cell proliferation, apoptosis and migration under drug (Sodium Salicylate, Cisplatin and 5-Fluorouracil) treatment. Sodium Salicylate is one of non-steroidal anti-inflammatory (NSAID) drug, which inhibits the downstream of NF-£eB pathway, e.g., COX-1. Cisplatin and 5-Fluorouracil are traditional chemotherapy durgs used in many cancers. Our result shows that overexpression of LMP1 affects cell proliferation, apoptosis , invasion and migration ability. It indicates that LMP1-overexpression is an important marker for NPC therapy.
|
16 |
The transdermal absorption of 5-Fluorouracil in the presence and absence of terpenes / Wilma SteenekampSteenekamp, Willem January 2003 (has links)
The skin is an amazingly resilient and relatively impermeable barrier that provides protective,
perceptive and communication functions to the body (Ramachandran & Fleisher, 2000). The
stratum corneum is widely accepted as the barrier of the skin - limiting the transport of
molecules into and across the skin. One of the bottlenecks in the successful development of
transdermal drug delivery devices is the fact that the skin (more accurately, the stratum corneum
- SC) tends to control the rate of drug transport. This makes it very difficult to influence or
regulate the transdermal drug absorption kinetics from outside, Le. by means of the vehicle. A
possible, and even elegant, solution may be the use of so-called "penetration enhancers",
thereby suppressing the dominant role of the stratum corneum penetration barrier (Bodde et al.,
1990).
For this study 5-fluorouracil (5-FU), a polar hydrophilic drug, was chosen as model drug to study
its penetration through the stratum corneum. Terpenes used as possible penetration enhancers
for 5-FU were menthol, isomenthol, menthone, l3-myrcene, limonene and 1,8-cineole. In
previous studies, terpenes with low skin irritancy and low systemic toxicity, were found to be
effective penetration enhancers for a number of hydrophilic and lipophillic drugs (Cornwell &
Barry, 1994; Cornwell et a/., 1996; Godwin & Michniak, 1999).
The objective of this study was to determine the different flux rates of 5-FU in the absence of
any pre-treatment of the stratum corneum and also through ethanol and selected terpene
pre-treated SC. The effect of each terpene on the penetration of 5-FU was determined. The
penetration of the selected terpenes themselves through the human stratum corneum was also
determined in vitro permeation studies were performed using vertical Franz diffusion cells with human skin
(stratum corneum). A saturated aqueous solution of 5-fluorouracil in the absence and presence
of pre-treatment of the SC was used as the donor phase. Pre-treatment was performed by
applying a 5 % terpene solution or absolute ethanol to the SC half an hour before the saturated
III
solution was applied in the donor compartment. A 50/50 ethanol/water solution was used as the
receptor phase. All the experiments were conducted over a 24 h period. The 37°C
temperature was held constant by means of a water bath. For the analysis of 5-FU flux rates,
samples from the receptor compartment were obtained and were analysed by means of high-pressure
liquid chromatography (HPLC). In order to determine the cumulative percentage of
terpenes penetrated through human stratum corneum, the samples were analysed by gas
chromatography (GC).
In this study, only menthol and isomenthol (both oxygen-containing terpenes) showed a
statistically significant increase on the flux of 5-FU, with flux values of 1.13 +- 0.38 and
1.45 +- 0.68 ug/cm2/h, respectively, compared to untreated skin with a flux value of 0.54 +- 0.23
ug/cm2/h for 5-FU. It was also proved that ethanol itself had an enhancing effect on 5-FU and
showed synergistic effects on the enhancement activities of all the terpenes. It was found that
all the terpenes (applied as a 5 % solution in ethanol) penetrated through the stratum corneum
in the absence of 5-fluorouracil. 5-Fluorouracil had either an increasing or decreasing effect on
the penetration of the terpenes.
From these findings, it could be concluded that oxygen-containing terpenes had the best
penetration enhancing effect on 5-FU and that menthol and isomenthol were the most effective
penetration enhancers, although the extend of penetration enhancement is not large enough for
clinical application. All the terpenes have the ability to penetrate through human stratum
corneum, and 5-FU either had an increasing or decreasing effect on their penetration. / Thesis (M.Sc.)--North-West University, Potchefstroom Campus, 2004.
|
17 |
Effect of Brij 97 in the presence and absence of carrageenan on the transdermal delivery of 5-Fluorouracil / Carli NeethlingNeethling, Catharina Elizabeth January 2006 (has links)
The skin is the largest and most easily accessible organ of the human body thus making it the ideal
route for systemic drug delivery. The transdermal route of drug delivery offers several advantages
compared to the traditional routes including elimination of first pass metabolism and higher patient
compliance. However, many drugs are topically and systemically ineffective when applied onto the
skin, due to their almost complete failure to penetrate the skin. The main limitation lies in the
stratum corneum, the barrier of the skin, which prevent the drug from reaching the deeper skin strata.
5-Fluorouracil is a polar hydrophilic drug and is therefore not a good penetrant through skin. A
popular technique to increase transdermal permeation is to use a penetration enhancer, which
reversibly reduce the permeability barrier of the stratum corneum. The primary aim of this study
was to determine the effect of Brij 97 in the presence and absence of carrageenan on the transdermal
delivery of 5-fluorouracil.
The formulations were identified by means of confocal laser scanning microscopy and measurement
of the particle size. The zeta-potential was measured to determine whether the formulations were
stable and the pH was measured to determine if the internal structures of the formulations were
affected by the drug. The drug released from the formulations was measured with a VanKel
dissolution apparatus. In vitro transdermal diffusion studies were performed using vertical Franz
diffusion cells with human epidermal skin. Histopathological studies were carried out on human
epidermis skin to determine if the surfactant, Brij 97, had any effect on the skin.
Through confocal laser scanning microscopy and particle size measurements, the 4 and 8% Brij 97
formulations without carrageenan could be identified as emulsions while the 15 and 25% Brij 97
formulations without carrageenan could be identified as microemulsions. The 4, 8, 15 and 25% Brij
97 formulations containing carrageenan could be identified as gels.
The results obtained from the zeta-potential analysis indicated that the 4 and 8% Brij 97 formulations
without carrageenan and 4% Brij 97 formulation with carrageenan are the most electronegative and
thus the most stable. The pH measurements confirmed that the internal structure of the formulations
was not influenced by the drug.
5-Fluorouracil was released from the formulations. The 4 and 8% Brij 97 formulations without
carrageenan had an enhancing effect on the penetration of 5-fluorouracil while the 4, 8, 15 and 25%
Brij 97 formulations with carrageenan and the 15 and 25% Brij 97 formulations without carrageenan
had an hindering effect on the penetration of 5-fluorouracil. Although carrageenan led to good
adhesiveness of the formulation on the skin, it did not lead to the enhancement of the penetration of
5-fluorouracil through the skin.
When histopathological studies were carried out on female human abdominal skin, Brij 97, the
surfactant, was found to have no damaging effect on the skin structure. / Thesis (M.Sc. (Pharmaceutics))--North-West University, Potchefstroom Campus, 2006.
|
18 |
Optimised topical delivery of 5-fluorouracilChinembiri, Tawona Nyasha January 2012 (has links)
Skin cancer is the most widely diagnosed form of cancer and it is split in to non-melanoma skin cancer (NMSC) and cutaneous malignant melanoma (CMM). Cutaneous melanoma has a high propensity for malignancy and it has the highest mortality rate of all skin cancers (de Gruijl, 1999:2004). The first line of treatment for most skin cancers is surgical excision but instances do arise in which surgery is not feasible due to the health of the patient or the location of the lesion. Therefore, viable alternatives are necessary in cases where surgery is not possible (Telfer et al., 2008:36). The skin is readily available for delivery of cytotoxic drugs to treat carcinomas and melanomas so the topical delivery of 5-fluorouracil was investigated in this study.
5-Fluorouracil is a pyrimidine anti-metabolite which interferes with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis by inhibiting the nucleotide synthetic enzyme thymidylate synthase (TS) and by becoming misincorporated into RNA and DNA. Thymidylate is essential for replication as well as repair of DNA, in the event of TS inhibition thymidylate is not formed and “thymineless deaths” of cells occur (Chu & Sartorelli, 2009:935; Longley et al., 2003:330). This active pharmaceutical ingredient (API) causes death of atypical and rapidly dividing cells (Tsuji & Karasek, 1986:474). The intravenous and topical routes are approved for 5-fluorouracil and in the case of skin cancer the obvious choice would be topical application (Chu & Sartorelli, 2009:935). Topical application of 5-fluorouracil results in the occurrence of terrible side effects such as severe inflammation, stomatitis, photosensitivity and dermatitis. A reduction in side effects would reduce the stigma associated with topical 5-fluorouracil and in turn increase patient compliance.
Topical drug delivery entails the delivery of an API onto or into the various layers of the skin (Flynn & Weiner, 1993:33) in order to treat conditions on or within the skin. Topical application of APIs is non-invasive, painless and simple plus the target site is readily accessible for topical therapy, thus the API is delivered directly to the site of action (Naik et al., 2000:318). In the case of skin cancer, 5-fluorouracil should be able to reach the epidermis because NMSC originates from the keratinocytes (Marks & Hanson, 2010:305) and CMM from melanocytes (de Gruijl, 1999:2004) which are both found in the epidermis. The barrier function of the skin limits the penetration of molecules into the skin and the rate-limiting step is usually penetration into the stratum corneum (Foldvari, 2000:418).
The aim of this study was to investigate the diffusion of 5-fluorouracil from formulations into and through the skin. Two physico-chemical properties of 5-fluorouracil that influence skin permeation were determined (aqueous solubility and n-octanol-buffer partition coefficient (log D)). The Pheroid™ drug delivery system was used to enhance the delivery of 5-fluorouracil (Grobler et al., 2008:284). Pheroid™ is a novel technology that is used in the delivery of APIs in pharmaceutical products. It enhances the efficacy of delivered compounds while allowing for the reduction of unwanted adverse effects (Grobler et al., 2008:284). Franz cell skin diffusion studies and tape-stripping were conducted with Pheroid™ and non-Pheroid™ formulations to allow for comparison and determination of the effect of Pheroid™. The in vitro efficacy of 5-fluorouracil in inducing apoptosis of human melanoma cells was investigated using a flow cytometric apoptosis assay. Different concentrations of 5-fluorouracil in formulation were utilised in the experiments so as to observe the cytotoxic effect of 5-fluorouracil. The effect of the drug delivery vehicle on the efficacy of 5-fluorouracil was investigated by utilising API solutions in addition to Pheroid™ and non-Pheroid™ formulations in the experiments.
Relatively high concentrations of 5-fluorouracil diffused into and through the skin with Pheroid™ formulations resulting in a greatly enhanced in vitro skin permeation of 5-fluorouracil. The tape-stripping revealed that the Pheroid™ lotions resulted in higher concentrations of 5-fluorouracil in the epidermis and dermis after 12 h as compared to the lotions. There was no deducible trend with respect to the distribution of 5-fluorouracil between the epidermis and dermis. Subsequent to the apoptosis assay it was found that 5-fluorouracil was able to induce apoptosis in A375 cells after a 24 h incubation period. The Pheroid™ treatment of cells resulted in a greater response (mean fluorescence intensity) as compared to treatments with the other drug delivery vehicles at three of the four concentrations. This showed that the drug delivery vehicle played a role in the in vitro efficacy of 5-fluorouracil.
Further research must be done in order to combine these results. Optimum and highly effective topical formulations with low doses of 5-fluorouracil must be formulated for the purpose of treating cutaneous cancers with a reduced incidence of side effects. / Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.
|
19 |
Optimised topical delivery of 5-fluorouracilChinembiri, Tawona Nyasha January 2012 (has links)
Skin cancer is the most widely diagnosed form of cancer and it is split in to non-melanoma skin cancer (NMSC) and cutaneous malignant melanoma (CMM). Cutaneous melanoma has a high propensity for malignancy and it has the highest mortality rate of all skin cancers (de Gruijl, 1999:2004). The first line of treatment for most skin cancers is surgical excision but instances do arise in which surgery is not feasible due to the health of the patient or the location of the lesion. Therefore, viable alternatives are necessary in cases where surgery is not possible (Telfer et al., 2008:36). The skin is readily available for delivery of cytotoxic drugs to treat carcinomas and melanomas so the topical delivery of 5-fluorouracil was investigated in this study.
5-Fluorouracil is a pyrimidine anti-metabolite which interferes with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis by inhibiting the nucleotide synthetic enzyme thymidylate synthase (TS) and by becoming misincorporated into RNA and DNA. Thymidylate is essential for replication as well as repair of DNA, in the event of TS inhibition thymidylate is not formed and “thymineless deaths” of cells occur (Chu & Sartorelli, 2009:935; Longley et al., 2003:330). This active pharmaceutical ingredient (API) causes death of atypical and rapidly dividing cells (Tsuji & Karasek, 1986:474). The intravenous and topical routes are approved for 5-fluorouracil and in the case of skin cancer the obvious choice would be topical application (Chu & Sartorelli, 2009:935). Topical application of 5-fluorouracil results in the occurrence of terrible side effects such as severe inflammation, stomatitis, photosensitivity and dermatitis. A reduction in side effects would reduce the stigma associated with topical 5-fluorouracil and in turn increase patient compliance.
Topical drug delivery entails the delivery of an API onto or into the various layers of the skin (Flynn & Weiner, 1993:33) in order to treat conditions on or within the skin. Topical application of APIs is non-invasive, painless and simple plus the target site is readily accessible for topical therapy, thus the API is delivered directly to the site of action (Naik et al., 2000:318). In the case of skin cancer, 5-fluorouracil should be able to reach the epidermis because NMSC originates from the keratinocytes (Marks & Hanson, 2010:305) and CMM from melanocytes (de Gruijl, 1999:2004) which are both found in the epidermis. The barrier function of the skin limits the penetration of molecules into the skin and the rate-limiting step is usually penetration into the stratum corneum (Foldvari, 2000:418).
The aim of this study was to investigate the diffusion of 5-fluorouracil from formulations into and through the skin. Two physico-chemical properties of 5-fluorouracil that influence skin permeation were determined (aqueous solubility and n-octanol-buffer partition coefficient (log D)). The Pheroid™ drug delivery system was used to enhance the delivery of 5-fluorouracil (Grobler et al., 2008:284). Pheroid™ is a novel technology that is used in the delivery of APIs in pharmaceutical products. It enhances the efficacy of delivered compounds while allowing for the reduction of unwanted adverse effects (Grobler et al., 2008:284). Franz cell skin diffusion studies and tape-stripping were conducted with Pheroid™ and non-Pheroid™ formulations to allow for comparison and determination of the effect of Pheroid™. The in vitro efficacy of 5-fluorouracil in inducing apoptosis of human melanoma cells was investigated using a flow cytometric apoptosis assay. Different concentrations of 5-fluorouracil in formulation were utilised in the experiments so as to observe the cytotoxic effect of 5-fluorouracil. The effect of the drug delivery vehicle on the efficacy of 5-fluorouracil was investigated by utilising API solutions in addition to Pheroid™ and non-Pheroid™ formulations in the experiments.
Relatively high concentrations of 5-fluorouracil diffused into and through the skin with Pheroid™ formulations resulting in a greatly enhanced in vitro skin permeation of 5-fluorouracil. The tape-stripping revealed that the Pheroid™ lotions resulted in higher concentrations of 5-fluorouracil in the epidermis and dermis after 12 h as compared to the lotions. There was no deducible trend with respect to the distribution of 5-fluorouracil between the epidermis and dermis. Subsequent to the apoptosis assay it was found that 5-fluorouracil was able to induce apoptosis in A375 cells after a 24 h incubation period. The Pheroid™ treatment of cells resulted in a greater response (mean fluorescence intensity) as compared to treatments with the other drug delivery vehicles at three of the four concentrations. This showed that the drug delivery vehicle played a role in the in vitro efficacy of 5-fluorouracil.
Further research must be done in order to combine these results. Optimum and highly effective topical formulations with low doses of 5-fluorouracil must be formulated for the purpose of treating cutaneous cancers with a reduced incidence of side effects. / Thesis (MSc (Pharmaceutics))--North-West University, Potchefstroom Campus, 2013.
|
20 |
The transdermal absorption of 5-Fluorouracil in the presence and absence of terpenes / Wilma SteenekampSteenekamp, Willem January 2003 (has links)
The skin is an amazingly resilient and relatively impermeable barrier that provides protective,
perceptive and communication functions to the body (Ramachandran & Fleisher, 2000). The
stratum corneum is widely accepted as the barrier of the skin - limiting the transport of
molecules into and across the skin. One of the bottlenecks in the successful development of
transdermal drug delivery devices is the fact that the skin (more accurately, the stratum corneum
- SC) tends to control the rate of drug transport. This makes it very difficult to influence or
regulate the transdermal drug absorption kinetics from outside, Le. by means of the vehicle. A
possible, and even elegant, solution may be the use of so-called "penetration enhancers",
thereby suppressing the dominant role of the stratum corneum penetration barrier (Bodde et al.,
1990).
For this study 5-fluorouracil (5-FU), a polar hydrophilic drug, was chosen as model drug to study
its penetration through the stratum corneum. Terpenes used as possible penetration enhancers
for 5-FU were menthol, isomenthol, menthone, l3-myrcene, limonene and 1,8-cineole. In
previous studies, terpenes with low skin irritancy and low systemic toxicity, were found to be
effective penetration enhancers for a number of hydrophilic and lipophillic drugs (Cornwell &
Barry, 1994; Cornwell et a/., 1996; Godwin & Michniak, 1999).
The objective of this study was to determine the different flux rates of 5-FU in the absence of
any pre-treatment of the stratum corneum and also through ethanol and selected terpene
pre-treated SC. The effect of each terpene on the penetration of 5-FU was determined. The
penetration of the selected terpenes themselves through the human stratum corneum was also
determined in vitro permeation studies were performed using vertical Franz diffusion cells with human skin
(stratum corneum). A saturated aqueous solution of 5-fluorouracil in the absence and presence
of pre-treatment of the SC was used as the donor phase. Pre-treatment was performed by
applying a 5 % terpene solution or absolute ethanol to the SC half an hour before the saturated
III
solution was applied in the donor compartment. A 50/50 ethanol/water solution was used as the
receptor phase. All the experiments were conducted over a 24 h period. The 37°C
temperature was held constant by means of a water bath. For the analysis of 5-FU flux rates,
samples from the receptor compartment were obtained and were analysed by means of high-pressure
liquid chromatography (HPLC). In order to determine the cumulative percentage of
terpenes penetrated through human stratum corneum, the samples were analysed by gas
chromatography (GC).
In this study, only menthol and isomenthol (both oxygen-containing terpenes) showed a
statistically significant increase on the flux of 5-FU, with flux values of 1.13 +- 0.38 and
1.45 +- 0.68 ug/cm2/h, respectively, compared to untreated skin with a flux value of 0.54 +- 0.23
ug/cm2/h for 5-FU. It was also proved that ethanol itself had an enhancing effect on 5-FU and
showed synergistic effects on the enhancement activities of all the terpenes. It was found that
all the terpenes (applied as a 5 % solution in ethanol) penetrated through the stratum corneum
in the absence of 5-fluorouracil. 5-Fluorouracil had either an increasing or decreasing effect on
the penetration of the terpenes.
From these findings, it could be concluded that oxygen-containing terpenes had the best
penetration enhancing effect on 5-FU and that menthol and isomenthol were the most effective
penetration enhancers, although the extend of penetration enhancement is not large enough for
clinical application. All the terpenes have the ability to penetrate through human stratum
corneum, and 5-FU either had an increasing or decreasing effect on their penetration. / Thesis (M.Sc.)--North-West University, Potchefstroom Campus, 2004.
|
Page generated in 0.131 seconds